Novavax, Inc. has announced preclinical data for its H5N1 avian pandemic influenza vaccine candidate, which demonstrated immunogenicity against currently circulating variants. The study, published in Nature Communications, showed that the vaccine, which utilizes Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses in nonhuman primates following either a single or two-dose administration via intranasal or intramuscular routes. The results indicated that even a single dose could potentially provide protective immunity, especially in individuals previously exposed to seasonal influenza. These findings suggest that Novavax's vaccine could play a significant role in pandemic emergency preparedness efforts. The company is seeking funding, partnership, and licensing opportunities to advance its H5N1 vaccine candidate.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.